Medical Products Executive joins TruScreen Board

NZX and Media Release 20 August 2018
NZX Limited
WELLINGTON

Experienced Medical Products Executive joins TruScreen Board

Cervical cancer technology company, TruScreen Ltd (NZAX, TRU), is pleased to announce the
appointment of Mr. Con Hickey as an independent director on the TruScreen board.
Mr Hickey has more than 30 years experience in the Medical Device industry, including
holding senior executive roles for multinational companies such as Welch Allyn, a leading
global manufacturer in frontline diagnostic and screening equipment. Currently the
Managing Partner of CONX Partners, Con’s particular skillset includes strategic planning,
channel management, talent development and business and market development. His
geographic expertise has been focused on the high growth countries of Asian Pacific region,
including China and India, with extensive global industry connections.
Chairman of TruScreen, Mr Robert Hunter, commented: “Mr Hickey brings a wealth of
relevant experience to TruScreen. He has a great commercial and sales background, which
is ideal for us as we move from a product improvement phase to full scale
commercialisation of our unique cancer screening technology.”
Mr Hickey is ordinarily a resident of New Zealand and has been appointed by the current
TruScreen directors, as permitted under TruScreen’s constitution. He will hold office until
TruScreen’s 2018 Annual Meeting at which time he will offer himself for re-election by
shareholders.

ENDS

For more information visit www.TruScreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@TruScreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial
neoplasia (CIN). A Single Use Sensor (SUS) is used
for each patient to protect against cross-infection.